49697-38-3CCC(=O)[C@@]1(C)[C@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@@]21CQTTRZHGPGKRAFB-PAIWTFDUSA-N49697-38-3CHEMBL111461안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Rimexolone, an ophthalmic corticosteroid, was launched in 1995 in the U.S.A. for the treatment of postoperative inflammation following ocular surgery and anterior uveitis. Rimexolone has high corticoid receptor affinity and is a potent local antiinflammatory agent with minimal systemic effects and virtually no atrophogenic action in many animal models studied, unique among a wide range of topical steroids. Rapid onset, long duration of action plus a superior safety profile are characteristics of rimexolone. It was also approved in Europe for the treatment of rheumatoid arthritis and is currently in clinical trials for tendinitis and osteoarthritis.
용도Anti-inflammatory (local).
일반 설명Rimexolone, 11β-hydroxy-16α,17α-dimethyl-17-(1-oxopropyl)androsta-1,4-diene-3-one,like medrysone and fluorometholone, lacks the C21 OHgroup. In addition, rimexolone has an additional methylgroup in the 17 -position, a site where an OH group is typicallyfound. Rimexolone is available as a suspension forophthalmic use.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…